{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=51", "query": { "intervention": "combined treatment", "page": 51 }, "page_size": 10 }, "pagination": { "page": 51, "page_size": 10, "total_count": 13972, "total_pages": 1398, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=52&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=50&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T15:27:43.029Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01923337", "title": "Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mucinous Adenocarcinoma of the Colon", "Mucinous Adenocarcinoma of the Rectum", "Recurrent Colon Cancer", "Recurrent Rectal Cancer", "Signet Ring Adenocarcinoma of the Colon", "Signet Ring Adenocarcinoma of the Rectum", "Stage IIIA Colon Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2013-08", "completion_date": "2016-10-17", "has_results": false, "last_update_posted_date": "2019-01-04", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01923337" }, { "nct_id": "NCT00892437", "title": "Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "COBI placebo", "type": "DRUG" }, { "name": "RTV placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2009-05", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-02-15", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00892437" }, { "nct_id": "NCT04057677", "title": "Exercise Training as an Intervention to Improve Muscle Function and Recovery Following Bed Rest in Older Adults With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 2 Diabetes", "Muscular Atrophy", "Sedentary Behavior", "Exercise", "Pre-diabetes" ], "interventions": [ { "name": "Bed Rest Intervention", "type": "BEHAVIORAL" }, { "name": "Exercise Program", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "AdventHealth Translational Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "60 Years to 80 Years" }, "enrollment_count": 12, "start_date": "2019-12-20", "completion_date": "2025-02-07", "has_results": false, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04057677" }, { "nct_id": "NCT00055757", "title": "Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "tipifarnib", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2003-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055757" }, { "nct_id": "NCT02725619", "title": "CBT for Anxiety in Children With Autism", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Autism Spectrum Disorder", "Anxiety" ], "interventions": [ { "name": "CBT", "type": "BEHAVIORAL" }, { "name": "PST", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Years", "maximum_age": "14 Years", "sex": "ALL", "summary": "8 Years to 14 Years" }, "enrollment_count": 70, "start_date": "2016-04", "completion_date": "2022-10-12", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02725619" }, { "nct_id": "NCT01642030", "title": "Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid Dependence", "Pain", "Addiction" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Hydromorphone", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 132, "start_date": "2013-08", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2017-09-11", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01642030" }, { "nct_id": "NCT05243628", "title": "Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Afrezza (insulin human) Inhalation Powder", "type": "BIOLOGICAL" }, { "name": "insulin degludec", "type": "BIOLOGICAL" }, { "name": "Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2022-03-31", "completion_date": "2022-10-17", "has_results": true, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 2, "location_summary": "Loma Linda, California • Austin, Texas", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243628" }, { "nct_id": "NCT06984328", "title": "Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)", "Metastatic Cutaneous Melanoma (Stage IV)" ], "interventions": [ { "name": "Acasunlimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2025-07-25", "completion_date": "2026-05-15", "has_results": true, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06984328" }, { "nct_id": "NCT04104139", "title": "TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rectal Adenocarcinoma", "Stage IIA Rectal Cancer AJCC v8", "Stage IIB Rectal Cancer AJCC v8", "Stage III Rectal Cancer AJCC v8", "Stage IIIA Rectal Cancer AJCC v8", "Stage IIIB Rectal Cancer AJCC v8", "Stage IIIC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Trifluridine and Tipiracil Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2019-12-11", "completion_date": "2025-07-15", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04104139" }, { "nct_id": "NCT02654639", "title": "Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2016-02", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2018-08-07", "last_synced_at": "2026-10-21T15:27:43.029Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02654639" } ] }